Hepatitis C News and Research

Latest Hepatitis C News and Research

Investing in new hepatitis C therapies may have significant economic impact

While a new generation of safer, more effective oral medications to treat hepatitis C patients may cost tens of thousands of dollars for a 12-week regiment, investing in these new therapies could generate savings estimated at more than $3.2 billion annually in the U.S. and five European countries, according to a new study (abstract 228) released today at Digestive Disease Week® (DDW) 2015.

18 May 2015

New test could identify resistant tuberculosis faster

Tuberculosis (TB) disease rates in some parts of London are as high as in Sub-Saharan Africa, and drug-resistant strains are becoming increasingly common.

From Oxford Gene Technology 14 May 2015

MD Anderson researchers find significant clinical variations among liver cancer patients

Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when developing treatment plans for newly diagnosed patients, according to researchers at The University of Texas MD Anderson Cancer Center.

14 May 2015

HHMI selects two Boston University medical students to conduct full-time biomedical research

Two medical students from Boston University have been selected by the Howard Hughes Medical Institute to conduct full-time biomedical research in its Medical Research Fellows Program. Joseph Park and Jacqueline Estevez are two of the selected 68 top medical and veterinary students from 37 different schools in the United States to receive this honor.

14 May 2015

TSRI researchers find interferon beta protein as prime suspect in persistent viral infections

Interferon proteins are normally considered virus-fighters, but scientists at The Scripps Research Institute have found evidence that one of them, interferon beta (IFNβ), has an immune-suppressing effect that can help some viruses establish persistent infections.

14 May 2015

UCL-led team develops new technique to find resistant TB faster

The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team. This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks.

From Oxford Gene Technology 13 May 2015

Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

A simple blood test can be used to predict which chronic hepatitis C patients will respond to interferon-based therapy, according to a report in the May issue of Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association.

13 May 2015

WHO Press Release: World Health Statistics reports on global health goals for 194 countries

Progress in child survival worldwide is one of the greatest success stories of international development. Since 1990, child deaths have almost halved – falling from an estimated 90 deaths per 1000 live births to 46 deaths per 1000 live births in 2013...

13 May 2015

Galmed reports net loss of $2.5 million for first quarter 2015

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, today announced financial results for the three months ended March 31, 2015.

13 May 2015

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

8 May 2015

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

The World Health Organization (WHO) today published the new edition of its Model List of Essential Medicines) which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others...

8 May 2015

Hepatitis C common among HIV-positive patients in sub-Saharan Africa

A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV...

7 May 2015

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

A 12-week dose of an investigational three-drug hepatitis C combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of The Journal of the American Medical Association.

7 May 2015

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Dr Matteo Iannacone of the San Raffaele Scientific Institute in Milan where intravital microscopy is being applied to the study of host-viruses and associated immune responses.

7 May 2015

New study finds high levels of HCV infection among HIV-infected people across Africa

A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV.

6 May 2015

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

5 May 2015

TDF switch effective in Asian chronic HBV patients

Switching therapy to tenofovir disoproxil fumarate is effective in treatment-resistant chronic hepatitis B, show results from a cohort of Asian patients.

29 Apr 2015

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

In patients with chronic hepatitis B virus infection, treatment with tenofovir disoproxil fumarate does not significantly increase the risk of developing renal dysfunction compared with entecavir treatment, a US team reports.

29 Apr 2015

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Tenofovir disoproxil fumarate alone elicits a response comparable to that of TDF plus entecavir in heavily pretreated patients with chronic hepatitis B virus infection resistant to adefovir dipivoxil, research suggests.

29 Apr 2015

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit.

29 Apr 2015

Hepatitis C News and Research

Latest Hepatitis C News and Research

Investing in new hepatitis C therapies may have significant economic impact

New test could identify resistant tuberculosis faster

MD Anderson researchers find significant clinical variations among liver cancer patients

HHMI selects two Boston University medical students to conduct full-time biomedical research

TSRI researchers find interferon beta protein as prime suspect in persistent viral infections

UCL-led team develops new technique to find resistant TB faster

Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

WHO Press Release: World Health Statistics reports on global health goals for 194 countries

Galmed reports net loss of $2.5 million for first quarter 2015

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

Hepatitis C common among HIV-positive patients in sub-Saharan Africa

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

New study finds high levels of HCV infection among HIV-infected people across Africa

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

TDF switch effective in Asian chronic HBV patients

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in